Navid Sobhani

TitlePostdoc Fellows and Associates
InstitutionBaylor College of Medicine
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y. CTLA-4 in Regulatory T Cells for Cancer Immunotherapy. Cancers (Basel). 2021 Mar 22; 13(6). PMID: 33809974.
    2. Roviello G, D'Angelo A, Sirico M, Pittacolo M, Conter FU, Sobhani N. Author Correction to: Advances in anti-BRAF therapies for lung cancer. Invest New Drugs. 2021 Mar 01. PMID: 33646490.
      Citations:    Fields:    
    3. Sobhani N, Fassl A, Mondani G, Generali D, Otto T. Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer. Cells. 2021 Feb 01; 10(2). PMID: 33535617.
      Citations:    Fields:    
    4. Roviello G, D'Angelo A, Sirico M, Pittacolo M, Conter FU, Sobhani N. Advances in anti-BRAF therapies for lung cancer. Invest New Drugs. 2021 Jan 21. PMID: 33474634.
      Citations:    Fields:    
    5. Sirico M, Bernocchi O, Sobhani N, Giudici F, Corona SP, Vernieri C, Nichetti F, Cappelletti MR, Milani M, Strina C, Cervoni V, Barbieri G, Ziglioli N, Dester M, Bianchi GV, De Braud F, Generali D. Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Cancers (Basel). 2020 Nov 10; 12(11). PMID: 33182575.
    6. D'Angelo A, Sobhani N, Chapman R, Bagby S, Bortoletti C, Traversini M, Ferrari K, Voltolini L, Darlow J, Roviello G. Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. Cancers (Basel). 2020 Nov 06; 12(11). PMID: 33172113.
    7. Schettini F, Sobhani N, Ianza A, Triulzi T, Molteni A, Lazzari MC, Strina C, Milani M, Corona SP, Sirico M, Bernocchi O, Giudici F, Cappelletti MR, Ciruelos E, Jerusalem G, Loi S, Fox SB, Generali D. Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. Breast Cancer Res Treat. 2020 Nov; 184(2):421-431. PMID: 32770287.
      Citations:    Fields:    
    8. Flores-Villanueva P, Sobhani N, Wang X, Li Y. MR1-Restricted T Cells in Cancer Immunotherapy. Cancers (Basel). 2020 Aug 03; 12(8). PMID: 32756356.
    9. Sobhani N, Sirico M, Generali D, Zanconati F, Scaggiante B. Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer. World J Clin Oncol. 2020 Jul 24; 11(7):450-463. PMID: 32821651.
    10. Sobhani N, D'Angelo A, Wang X, Young KH, Generali D, Li Y. Mutant p53 as an Antigen in Cancer Immunotherapy. Int J Mol Sci. 2020 Jun 08; 21(11). PMID: 32521648.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    11. D'Angelo A, Sobhani N, Bagby S, Casadei-Gardini A, Roviello G. Cabozantinib as a second-line treatment option in hepatocellular carcinoma. Expert Rev Clin Pharmacol. 2020 Jun; 13(6):623-629. PMID: 32394749.
      Citations: 1     Fields:    Translation:HumansAnimals
    12. Sobhani N, Corona SP, Roviello G, Bagby S, D'Angelo A, Iezzi G, Generali D. Immune-gene signature: a new tool for patient selection for checkpoint inhibitors? Future Oncol. 2020 Jul; 16(19):1327-1330. PMID: 32396404.
      Citations:    Fields:    Translation:HumansCells
    13. Roviello G, Sobhani N, Corona SP, D'Angelo A. Corticosteroid switch after progression on abiraterone acetate plus prednisone. Int J Clin Oncol. 2020 Feb; 25(2):240-246. PMID: 31705219.
      Citations:    Fields:    Translation:Humans
    14. D'Angelo A, Sobhani N, Roviello G, Bagby S, Bonazza D, Bottin C, Giudici F, Zanconati F, De Manzini N, Guglielmi A, Generali D. Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma. PLoS One. 2019; 14(8):e0219566. PMID: 31381571.
      Citations: 4     Fields:    Translation:HumansCells
    15. Roviello G, Conter FU, Mini E, Generali D, Traversini M, Lavacchi D, Nobili S, Sobhani N. Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer. Cancer Chemother Pharmacol. 2019 10; 84(4):669-677. PMID: 31187168.
      Citations: 1     Fields:    Translation:Humans
    16. Roviello G, D'Angelo A, Generali D, Pittacolo M, Ganzinelli M, Iezzi G, Manzini N, Sobhani N. Avelumab in gastric cancer. Immunotherapy. 2019 06; 11(9):759-768. PMID: 31060469.
      Citations: 1     Fields:    Translation:Humans
    17. Sobhani N, D'Angelo A, Pittacolo M, Roviello G, Miccoli A, Corona SP, Bernocchi O, Generali D, Otto T. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer. Cells. 2019 04 06; 8(4). PMID: 30959874.
      Citations: 19     Fields:    Translation:HumansAnimals
    18. Sobhani N, Roviello G, Pivetta T, Ianza A, Bonazza D, Zanconati F, Giudici F, Bottin C, Corona SP, Guglielmi A, Rizzardi C, Milione M, Cortale M, Confalonieri M, Generali D. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma. Mol Biol Rep. 2019 Jun; 46(3):2713-2720. PMID: 30840203.
      Citations: 2     Fields:    Translation:HumansCells
    19. Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B. Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer. World J Clin Oncol. 2018 Dec 20; 9(8):172-179. PMID: 30622925.
      Citations: 4     
    20. Sobhani N, Generali D, D'Angelo A, Aieta M, Roviello G. Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer. Invest New Drugs. 2018 12; 36(6):1133-1137. PMID: 30083960.
      Citations: 8     Fields:    Translation:HumansCells
    21. Sobhani N, Ianza A, D'Angelo A, Roviello G, Giudici F, Bortul M, Zanconati F, Bottin C, Generali D. Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer. Cells. 2018 Jul 15; 7(7). PMID: 30011957.
      Citations: 15     Fields:    
    22. Roviello G, Corona SP, Bozza G, Aieta M, Generali D, Rodriquenz MG, Mileo AM, Imperatori M, Ianza A, Conca R, Sobhani N. Lenvatinib for the treatment of renal cell carcinoma. Expert Opin Investig Drugs. 2018 05; 27(5):507-512. PMID: 29718721.
      Citations: 1     Fields:    Translation:HumansAnimals
    23. Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B. Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives? World J Clin Oncol. 2018 Apr 10; 9(2):26-32. PMID: 29651384.
      Citations: 3     
    24. Sobhani N, Roviello G, Corona SP, Scaltriti M, Ianza A, Bortul M, Zanconati F, Generali D. The prognostic value of PI3K mutational status in breast cancer: A meta-analysis. J Cell Biochem. 2018 06; 119(6):4287-4292. PMID: 29345357.
      Citations: 14     Fields:    Translation:HumansCells
    25. Sobhani N, Corona SP, Bonazza D, Ianza A, Pivetta T, Roviello G, Cortale M, Guglielmi A, Zanconati F, Generali D. Advances in systemic therapy for malignant mesothelioma: future perspectives. Future Oncol. 2017 Oct; 13(23):2083-2101. PMID: 28984470.
      Citations: 1     Fields:    Translation:Humans
    26. Roviello G, Sobhani N, Generali D. Bevacizumab in small cell lung cancer. Ann Transl Med. 2017 Sep; 5(17):361. PMID: 28936455.
      Citations: 2     
    27. Sobhani N, Roviello G, Corona SP, Ianza A, Zanconati F, Generali D. Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma. Lung Cancer. 2017 12; 114:103-105. PMID: 28757047.
      Citations:    Fields:    Translation:Humans
    28. Sobhani N, Generali D, Roviello G. PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy. EBioMedicine. 2017 08; 22:18-19. PMID: 28688823.
      Citations: 1     Fields:    Translation:Humans
    29. Corona SP, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M, Zanconati F, Generali D. Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives. Med Oncol. 2017 07; 34(7):130. PMID: 28616710.
      Citations:    Fields:    
    30. Corona SP, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M, Zanconati F, Generali D. Advances in systemic therapy for metastatic breast cancer: future perspectives. Med Oncol. 2017 Jul; 34(7):119. PMID: 28526922.
      Citations: 11     Fields:    Translation:Humans
    31. Sobhani N, Corona SP, Zanconati F, Generali D. Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma. Genes Cancer. 2017 Mar; 8(3-4):495-496. PMID: 28680533.
      Citations: 5     
    Sobhani's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (89)
    Co-Authors (1)
    Similar People (60)
    Same Department Expand Description